News

The OX51 project aims to develop a sublingual dosage form for the treatment of acute intensive pain episodes in relation to care-related diagnostic or therapeutic procedures for patients

The NBER researchers are expected to use the data from Medidata’s proprietary clinical trial cost databases PICAS and CROCAS, accessed through Medidata Grants Manager and Medidata CRO Contractor,

The licensed technology relates to the discoveries that miR-33a and miR-33b down-regulate target genes involved in cholesterol transport and genes related to metabolic syndrome. Additionally, Regulus also controls

Oracle claims Health Sciences LabPas helps to manage the workflow and offer real-time access to data. ICON is a provider of outsourced development services to the pharmaceutical, biotechnology

Multikine is CEL-SCI’s immunotherapy which was developed as a standard of care in treating head and neck cancer. The Phase III trial is designed to determine if Multikine

BioSante Pharma said that LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The efficacy

Zalicus said that the US patent no. 7,915,265 entitled ‘Combinations for the Treatment of Immunoinflammatory Disorders’ offers coverage for Synavive through August 2025. Synavive is indicated for the

MicroCHIPS claims that the current patent in combination with US patent no. 7,070,590 offers coverage for the design and fabrication of reservoir-based medical devices used for implantable drug

Valeant is planning to commence a consent solicitation process during the week of April 4th in an effort to replace Cephalon’s current Board of Directors with its own